Evidence map›Paper›PMID 25583879›Full record

ArticleThe Journal of pharmacology and experimental therapeutics2015

A selective orexin-1 receptor antagonist attenuates stress-induced hyperarousal without hypnotic effects.

Pascal Bonaventure, Sujin Yun, Philip L Johnson, Anantha Shekhar, Stephanie D Fitz, Brock T Shireman, Terry P Lebold, Diane Nepomuceno, Brian Lord, Michelle Wennerholm and 4 more

Registry-linked trialOpen access · bronzeAbstract read
In one paragraph

Article in The Journal of pharmacology and experimental therapeutics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02593682 (The Role of Orexin in Human Panic Disorder), which is not on this map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
6.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02593682 phase4completednot on this mapstarted 2016, after this paper: background citation

The Role of Orexin in Human Panic Disorder

TypeinterventionalSponsorUniversity of California, San FranciscoRan2016 to 2020Enrolled3ConditionsPanic DisorderArmssuvorexant, placebo
3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 96 citations in OpenAlex.

  1. Review
  2. Article
  3. Antagonization of OXInternational journal of molecular sciences · 2022
    Article
  4. Article
  5. Article
  6. Behavioral and Physiologic Effects of Dirty Bedding Exposure in Female ICR Mice.Journal of the American Association for Laboratory Animal Science : JAALAS · 2022
    Article
  7. Article
  8. Hypocretin/Orexin Receptor Pharmacology and Sleep Phases.Frontiers of neurology and neuroscience · 2021
    Review
  9. Review
  10. Hypocretin (Orexin) Replacement Therapies.Medicine in drug discovery · 2020
    Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Orexins and stress.Frontiers in neuroendocrinology · 2018
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 1 country.

Pascal BonaventureJanssen Research & Development, LLC, San Diego, California (P.B., S.Y., B.T.S., T.P.L., D.N., B.L., M.W., J.S., N.C., T.L., C.D.); and Indiana University School of Medicine, Indianapolis, Indiana (P.L.J., A.S., S.D.F.) Pbonave1@its.jnj.com CDugovic@its.jnj.com.
Sujin YunJanssen Research & Development, LLC, San Diego, California (P.B., S.Y., B.T.S., T.P.L., D.N., B.L., M.W., J.S., N.C., T.L., C.D.); and Indiana University School of Medicine, Indianapolis, Indiana (P.L.J., A.S., S.D.F.).
Philip L JohnsonJanssen Research & Development, LLC, San Diego, California (P.B., S.Y., B.T.S., T.P.L., D.N., B.L., M.W., J.S., N.C., T.L., C.D.); and Indiana University School of Medicine, Indianapolis, Indiana (P.L.J., A.S., S.D.F.).
Anantha ShekharJanssen Research & Development, LLC, San Diego, California (P.B., S.Y., B.T.S., T.P.L., D.N., B.L., M.W., J.S., N.C., T.L., C.D.); and Indiana University School of Medicine, Indianapolis, Indiana (P.L.J., A.S., S.D.F.).
Stephanie D FitzJanssen Research & Development, LLC, San Diego, California (P.B., S.Y., B.T.S., T.P.L., D.N., B.L., M.W., J.S., N.C., T.L., C.D.); and Indiana University School of Medicine, Indianapolis, Indiana (P.L.J., A.S., S.D.F.).
Brock T ShiremanJanssen Research & Development, LLC, San Diego, California (P.B., S.Y., B.T.S., T.P.L., D.N., B.L., M.W., J.S., N.C., T.L., C.D.); and Indiana University School of Medicine, Indianapolis, Indiana (P.L.J., A.S., S.D.F.).
Terry P LeboldJanssen Research & Development, LLC, San Diego, California (P.B., S.Y., B.T.S., T.P.L., D.N., B.L., M.W., J.S., N.C., T.L., C.D.); and Indiana University School of Medicine, Indianapolis, Indiana (P.L.J., A.S., S.D.F.).
Diane NepomucenoJanssen Research & Development, LLC, San Diego, California (P.B., S.Y., B.T.S., T.P.L., D.N., B.L., M.W., J.S., N.C., T.L., C.D.); and Indiana University School of Medicine, Indianapolis, Indiana (P.L.J., A.S., S.D.F.).
Brian LordJanssen Research & Development, LLC, San Diego, California (P.B., S.Y., B.T.S., T.P.L., D.N., B.L., M.W., J.S., N.C., T.L., C.D.); and Indiana University School of Medicine, Indianapolis, Indiana (P.L.J., A.S., S.D.F.).
Michelle WennerholmJanssen Research & Development, LLC, San Diego, California (P.B., S.Y., B.T.S., T.P.L., D.N., B.L., M.W., J.S., N.C., T.L., C.D.); and Indiana University School of Medicine, Indianapolis, Indiana (P.L.J., A.S., S.D.F.).
Jonathan SheltonJanssen Research & Development, LLC, San Diego, California (P.B., S.Y., B.T.S., T.P.L., D.N., B.L., M.W., J.S., N.C., T.L., C.D.); and Indiana University School of Medicine, Indianapolis, Indiana (P.L.J., A.S., S.D.F.).
Nicholas CarruthersJanssen Research & Development, LLC, San Diego, California (P.B., S.Y., B.T.S., T.P.L., D.N., B.L., M.W., J.S., N.C., T.L., C.D.); and Indiana University School of Medicine, Indianapolis, Indiana (P.L.J., A.S., S.D.F.).
Timothy LovenbergJanssen Research & Development, LLC, San Diego, California (P.B., S.Y., B.T.S., T.P.L., D.N., B.L., M.W., J.S., N.C., T.L., C.D.); and Indiana University School of Medicine, Indianapolis, Indiana (P.L.J., A.S., S.D.F.).
Christine DugovicJanssen Research & Development, LLC, San Diego, California (P.B., S.Y., B.T.S., T.P.L., D.N., B.L., M.W., J.S., N.C., T.L., C.D.); and Indiana University School of Medicine, Indianapolis, Indiana (P.L.J., A.S., S.D.F.).
Janssen (United States) · USHesco (United States) · USIndiana University – Purdue University Indianapolis · USIndiana University School of Medicine

Funding

Quality Assurance and Quality Control Project Management: Improving Submissions and Study Conduct in the Human Subjects Research Prior Approval ProcessUL1TR002529 · NCATS · INDIANA UNIVERSITY INDIANAPOLIS · PI MOE, SHARON M, WIEHE, SARAH ELIZABETH · 2018 to 2022
$27.2M
Indiana Clinical and Translational Sciences InstituteUL1TR001108 · NCATS · INDIANA UNIVERSITY INDIANAPOLIS · PI DENNE, SCOTT C., SHEKHAR, ANANTHA · 2013 to 2017
$23.3M
INDIANA CLINICAL AND TRANSLATIONAL SCIENCE INSTITUTE (UL1): BPCAUL1RR025761 · NCRR · INDIANA UNIVERSITY INDIANAPOLIS · PI SHEKHAR, ANANTHA · 2008 to 2011
$21.0M
NEUROBIOLOGY OF PANIC AND ANXIETY DISORDERSR01MH052619 · NIMH · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI SHEKHAR, ANANTHA · 1996 to 2016
$5.0M
Serotonin and CRF Pathways in Anxiety &HPA RegulationR01MH065702 · NIMH · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI LOWRY, CHRISTOPHER A, SHEKHAR, ANANTHA · 2003 to 2013
$2.8M
Hypothalamic Orexin Role in Menopause-Associated Hot Flashes and Mood/Sleep DisruK01AG044466 · NIA · INDIANA UNIVERSITY INDIANAPOLIS · PI JOHNSON, PHILIP LEE · 2013 to 2016
$467k
NCATS NIH HHS UL1 TR001108NCRR NIH HHS UL1 RR025761NCRR NIH HHS UL1-RR025761NIA NIH HHS 1K01-AG044466-01A1NIA NIH HHS K01 AG044466NIMH NIH HHS R01 MH052619NIMH NIH HHS R01 MH065702NIMH NIH HHS R01-MH52619NIMH NIH HHS R01-MH65702
6 · The paper itself

Abstract

Orexins (OXs) are peptides produced by perifornical (PeF) and lateral hypothalamic neurons that exert a prominent role in arousal-related processes, including stress. A critical role for the orexin-1 receptor (OX1R) in complex emotional behavior is emerging, such as overactivation of the OX1R pathway being associated with panic or anxiety states. Here we characterize a brain-penetrant, selective, and high-affinity OX1R antagonist, compound 56 [N-({3-[(3-ethoxy-6-methylpyridin-2-yl)carbonyl]-3-azabicyclo[4.1.0]hept-4-yl}methyl)-5-(trifluoromethyl)pyrimidin-2-amine]. Ex vivo receptor binding studies demonstrated that, after subcutaneous administration, compound 56 crossed the blood-brain barrier and occupied OX1Rs in the rat brain at lower doses than standard OX1R antagonists GSK-1059865 [5-bromo-N-({1-[(3-fluoro-2-methoxyphenyl)carbonyl]-5-methylpiperidin-2-yl}methyl)pyridin-2-amine], SB-334867 [1-(2-methyl-1,3-benzoxazol-6-yl)-3-(1,5-naphthyridin-4-yl)urea], and SB-408124 [1-(6,8-difluoro-2-methylquinolin-4-yl)-3-[4-(dimethylamino)phenyl]urea]. Although compound 56 did not alter spontaneous sleep in rats and in wild-type mice, its administration in orexin-2 receptor knockout mice selectively promoted rapid eye movement sleep, demonstrating target engagement and specific OX1R blockade. In a rat model of psychological stress induced by cage exchange, the OX1R antagonist prevented the prolongation of sleep onset without affecting sleep duration. In a rat model of panic vulnerability (involving disinhibition of the PeF OX region) to threatening internal state changes (i.e., intravenous sodium lactate infusion), compound 56 attenuated sodium lactate-induced panic-like behaviors and cardiovascular responses without altering baseline locomotor or autonomic activity. In conclusion, OX1R antagonism represents a novel therapeutic strategy for the treatment of various psychiatric disorders associated with stress or hyperarousal states.

Indexed as

Orexin Receptor AntagonistsAminopyridinesAnimalsArousalCHO CellsCricetinaeCricetulusHEK293 CellsHumansHypnotics and SedativesMaleMiceMice, Inbred C57BLMice, KnockoutOrexin ReceptorsPiperidines5-bromo-N-(1-(3-fluoro-2-methoxybenzoyl)-5-methylpiperidin-2-yl)methylpyridin-2-amineAminopyridinesHypnotics and SedativesOrexin Receptor AntagonistsOrexin ReceptorsPiperidines

Identifiers

PMID25583879
PMCPMC4352589
OpenAlexW2102943634

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.